Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Pancreatic cancer natural history

Introduction

Overview

Overview

Pancreatic ductal adenocarcinoma (PDAC) accounts for most pancreatic malignancies. It arises from precursor lesions through stepwise accumulation of KRAS, CDKN2A, TP53, and SMAD4 alterations.[1] At the molecular level the disease develops over many years, but it progresses rapidly once clinically apparent.[2] The major complications are:

Overall 5-year relative survival is about 12%. It is about 46% for localized disease and about 3% for distant disease.[3]

Natural History

Natural History

Precursor lesions and molecular progression

Timeline of progression

  • Genomic modeling estimates the following intervals:[2]
    • About 10–12 years from the initiating mutation to the founder non-metastatic clone.
    • About 6–7 further years to the metastatic clone.
    • About 2–3 years from dissemination to death.
  • A microsimulation model gave these estimates for lesions that became malignant:[4]
    • Mean time from onset to cancer was about 9.0 years for PanIN and 8.8 years for cysts.
    • Progression from high-grade dysplasia to cancer took about 4 years.
  • This long latency is a theoretical window for early detection.

Pattern of spread and clinical course

  • The liver is the most common site of initial metastasis, far more common than the lung.[5]
  • Tumor location shapes how the disease presents:[6]
    • Head tumors tend to present earlier, with obstructive jaundice.
    • Body/tail tumors present later, with abdominal or back pain, and are usually advanced at diagnosis.
  • Early disease is asymptomatic or causes nonspecific symptoms. Treatment is stratified by resectability category: resectable, borderline resectable, locally advanced, or metastatic.[6]
  • At diagnosis in the United States (SEER):[3]
    • About 13% of cases are localized.
    • About 29% are regional.
    • About 51% are distant (metastatic).
  • New-onset diabetes mellitus can precede the diagnosis.[6]
Complications

Complications

Biliary and gastric outlet obstruction

  • Endoscopic stent placement is used to relieve biliary obstruction.[7]
  • Duodenal obstruction is managed with endoscopic enteral stenting or gastrojejunostomy.[7]
    • Stents give faster symptom relief.
    • Gastrojejunostomy is more durable.
    • The choice depends on expected survival.[6]

Pain

  • Abdominal or back pain is reported in up to 62% of patients before diagnosis.[8]
  • Causes include perineural invasion, visceral ingrowth, pancreatic duct obstruction, and metastases.
  • Management steps up from opioids to interventional options, including EUS-guided celiac plexus neurolysis.[8]
  • The effect of neurolysis usually lasts about 1–3 months, so it is best suited to patients with limited life expectancy.

Exocrine pancreatic insufficiency

  • Exocrine pancreatic insufficiency (EPI) affects about 72% (95% CI 55–86%) of patients with advanced PDAC.[9]
  • It is significantly more common with pancreatic head tumors (RR 3.36, 95% CI 1.07–10.54).
  • Pancreatic enzyme replacement therapy (PERT) was associated with a 3.8-month survival benefit (95% CI 1.37–6.19).[9]

Cancer cachexia

  • Cancer cachexia is present in about 63% of patients at diagnosis.[8]
  • It reduces tolerance of treatment and worsens survival.
  • No pharmacotherapy is approved.
  • Investigational: the GDF-15 antibody ponsegromab increased body weight in a phase 2 trial in cancer cachexia.[10]

Venous thromboembolism

  • PDAC carries one of the highest VTE risks of any solid tumor. About 1 in 5 newly diagnosed patients develop VTE.[11]
  • In the prospective BACAP cohort:[12]
    • Cumulative VTE incidence was 8.1% at 3 months and 19.2% at 12 months.
    • About half of events were incidental (asymptomatic).
    • Locally advanced or metastatic stage was an independent risk factor.
    • VTE independently predicted shorter progression-free and overall survival.
  • Prophylaxis: ITAC recommends primary prophylaxis for ambulatory patients with locally advanced or metastatic pancreatic cancer who are receiving systemic anticancer therapy and have low bleeding risk.[13]
  • Treatment of established VTE: LMWH or a direct oral anticoagulant (DOAC) is recommended. DOACs carry a higher bleeding risk in luminal gastrointestinal cancers.[14]

Other complications

Areas of uncertainty

  • Scope of ambulatory thromboprophylaxis:
    • ASCO recommends offering prophylaxis to high-risk outpatients (Khorana score ≥2) starting systemic therapy.[14]
    • ITAC specifically targets locally advanced or metastatic pancreatic cancer.[13]
  • PERT and survival: the survival benefit comes from meta-analysis of predominantly non-randomized data.[9]
  • Incidental splanchnic vein thrombosis: the benefit of anticoagulation is uncertain and should be decided case by case.[7]
Prognosis

Prognosis

Overall outlook

Over the last decade, overall 5-year survival rose from 6% to 12%.[3]

  • The gain is concentrated in localized disease, where survival rose from 24% to 46%.
  • Survival for distant disease rose only from 2% to 3%.

Stage-specific survival

Staging uses the AJCC 8th edition TNM system:[15]

  • T category is defined by tumor size: T1 ≤2 cm, T2 >2–4 cm, T3 >4 cm.
  • N category is defined by the number of positive nodes: N1 = 1–3, N2 ≥4.
SEER summary stage: proportion at diagnosis and 5-year relative survival
Summary stage Proportion at diagnosis 5-year relative survival
Localized ~13% ~46%
Regional ~29% ~15%
Distant (metastatic) ~51% ~3%

[3]

Actual (observed, not actuarial) 5-year survival by AJCC stage in a real-world SEER cohort was:[16]

  • Stage IA: 31.7%
  • Stage IB: 11.8%
  • Stage IIA: 9.0%
  • Stage IIB: 8.7%
  • Stage III: 1.9%
  • Stage IV: 0.5%

Prognostic factors

Setting Independent prognostic factors
Resected disease Nodal status, T stage, and tumor grade. Resection margin is also associated with survival where it was recorded.[17]
After neoadjuvant therapy and resection Margin status, nodal disease, AJCC T stage, and normalization of CA 19-9. Age, sex, perineural invasion, baseline tumor size, and baseline CA 19-9 are not independently prognostic.[18]
Metastatic disease Initial lung metastasis is associated with lower risk of death than initial liver metastasis (HR 0.61).[5] VTE independently predicts shorter survival.[12]
  • The weight of prognostic factors changes over time.[19]
    • Aggressive tumor biology drives early mortality.
    • After neoadjuvant therapy, frailty and comorbidity become more important to later survival.
References

References

  1. ↑ 1.0 1.1 1.2 Ryan DP, Hong TS, Bardeesy N (2014). “Pancreatic adenocarcinoma”. N Engl J Med. 371 (11): 1039–49. doi:10.1056/NEJMra1404198. PMID 25207767.
  2. ↑ 2.0 2.1 Connor AA, Gallinger S (2022). “Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data”. Nat Rev Cancer. 22 (3): 131–142. doi:10.1038/s41568-021-00418-1. PMID 34789870 Check |pmid= value (help).
  3. ↑ 3.0 3.1 3.2 3.3 Rahib L, Coffin T, Kenner B (2025). “Factors Driving Pancreatic Cancer Survival Rates”. Pancreas. 54 (6): e530–e536. PMC 12175802 Check |pmc= value (help).
  4. ↑ 4.0 4.1 4.2 Koopmann B, Dunnewind N, van Duuren LA, Lansdorp-Vogelaar I, Naber SK, Cahen DL, Bruno MJ, de Kok I (2023). “The Natural Disease Course of Pancreatic Cyst-Associated Neoplasia, Dysplasia, and Ductal Adenocarcinoma: Results of a Microsimulation Model”. Gastroenterology. 165 (6): 1522–1532. doi:10.1053/j.gastro.2023.08.027. PMID 37633497 Check |pmid= value (help). Vancouver style error: initials (help)
  5. ↑ 5.0 5.1 Mancheski E, Baek D, Bowne W, Lavu H, Yeo CJ, Nevler A (2026). “Initial Site of Metastasis Influences Prognosis in Pancreatic Ductal Adenocarcinoma”. Cancer Med. 15 (4): e71760. doi:10.1002/cam4.71760. PMID 41889072 Check |pmid= value (help).
  6. ↑ 6.0 6.1 6.2 6.3 6.4 Park W, Chawla A, O’Reilly EM (2021). “Pancreatic Cancer: A Review”. JAMA. 326 (9): 851–862. doi:10.1001/jama.2021.13027. PMID 34547082 Check |pmid= value (help).
  7. ↑ 7.0 7.1 7.2 7.3 Sohal D, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O’Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru DA (2020). “Metastatic Pancreatic Cancer: ASCO Guideline Update”. J Clin Oncol. 38 (27): 3217–3230. doi:10.1200/JCO.20.01364. PMID 32755482 Check |pmid= value (help). Vancouver style error: initials (help)
  8. ↑ 8.0 8.1 8.2 Stoop TF, Javed AA, Oba A, Groot Koerkamp B, Seufferlein T, Wilmink JW, Besselink MG (2025). “Pancreatic cancer”. Lancet. 405 (10485): 1182–1202. doi:10.1016/S0140-6736(25)00261-2. PMID 40187844 Check |pmid= value (help).
  9. ↑ 9.0 9.1 9.2 de la Iglesia D, Avci B, Kiriukova M, Panic N, Bozhychko M, Sandru V, de-Madaria E, Capurso G (2020). “Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis”. United European Gastroenterol J. 8 (9): 1115–1125. doi:10.1177/2050640620938987. PMID 32631175 Check |pmid= value (help).
  10. ↑ Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR (2024). “Ponsegromab for the Treatment of Cancer Cachexia”. N Engl J Med. 391 (24): 2291–2303. doi:10.1056/NEJMoa2409515. PMID 39282907 Check |pmid= value (help).
  11. ↑ Willems R, Michiels N, Lanting VR, Bouwense S, van den Broek B, Graus M, Klok FA, Groot Koerkamp B, de Laat B, Roest M, Wilmink JW, van Es N, Mieog J, ten Cate H, de Vos-Geelen J (2023). “Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care”. Cancers (Basel). 15 (14): 3546. doi:10.3390/cancers15143546. PMID 37509209 Check |pmid= value (help). Vancouver style error: initials (help)
  12. ↑ 12.0 12.1 Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D (2020). “Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes”. Gastroenterology. 158 (5): 1346–1358.e4. doi:10.1053/j.gastro.2019.12.009. PMID 31843588.
  13. ↑ 13.0 13.1 Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J (2022). “2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19”. Lancet Oncol. 23 (7): e334–e347. doi:10.1016/S1470-2045(22)00160-7. PMID 35772465 Check |pmid= value (help).
  14. ↑ 14.0 14.1 Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee A, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A (2023). “Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update”. J Clin Oncol. 41 (16): 3063–3071. doi:10.1200/JCO.23.00294. PMID 37075273 Check |pmid= value (help). Vancouver style error: initials (help)
  15. ↑ Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017). AJCC Cancer Staging Manual (8th ed.). New York: Springer. ISBN 978-3-319-40617-6.
  16. ↑ Bengtsson A, Andersson R, Ansari D (2020). “The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data”. Sci Rep. 10 (1): 16425. doi:10.1038/s41598-020-73525-y. PMID 33009477 Check |pmid= value (help).
  17. ↑ Huang L, Balavarca Y, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Zadnik V, Primic-Žakelj M, Mägi M, Grützmann R, Besselink MG, Schrotz-King P, Brenner H, Jansen L (2019). “Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study”. BMC Med. 17 (1): 66. doi:10.1186/s12916-019-1304-y. PMID 30905320.
  18. ↑ Javed AA, Habib A, Mahmud O, Fatimi AS, Grewal M, Mughal N, He J, Wolfgang CL, Daamen L, Besselink MG (2025). “Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis”. J Natl Cancer Inst. 117 (5): 840–867. doi:10.1093/jnci/djae294. PMID 39563429 Check |pmid= value (help).
  19. ↑ Javed AA, Fatimi AS, Rompen IF, Mahmud O, van Goor I, Habib JR, Andel P, Campbell BA, Schouten TJ, Bagante F, Mughal NA, Stoop TF, Lafaro KJ, Burkhart RA, Burns WR, Hewitt DB, Sacks GD, van Santvoort HC, den Dulk M, Daams F, Mieog J, Stommel M, Patijn GA, de Hingh I, Festen S, Nijkamp MW, Klaase JM, Lips DJ, Wijsman JH, van der Harst E, Manusama ER, van Eijck C, Groot Koerkamp B, Kazemier G, Busch OR, Molenaar IQ, Daamen LA, Besselink MG, He J, Wolfgang CL (2025). “Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma”. J Natl Cancer Inst. 117 (12): 2526–2534. doi:10.1093/jnci/djaf196. PMID 40900668 Check |pmid= value (help). Vancouver style error: initials (help)


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Aravind Reddy Kothagadi M.B.B.S[3] Sudarshana Datta, MD [4]